Compared to the 2016 classification, IDH-mutant tumors have been excluded from this subset, while part of the IDH-wildtype tumors may now be reclassified as pediatric-type diffuse gliomas or other types of CNS tumors. This evidence concerns the gene IDH1 and central nervous system neoplasm.